BACKGROUND Complex cardiovascular surgery often results in postoperative hemorrhage. Excessive blood product use may cause systemic thrombosis, end-organ dysfunction, and edema preventing chest closure. Recombinant activated factor VII (rFVIIa) concentrate may decrease hemorrhage where other treatment measures failed. We reviewed our experience with rFVIIa after complex cardiovascular surgery. ...

BACKGROUND Changes in the Jehovah's Witness (JW) blood refusal policy now give members the personal choice to accept certain processed fractions of blood, such as factor concentrates and cryoprecipitate. METHODS Two JW patients undergoing complex aortic surgery who developed severe microvascular bleeding after prolonged use of cardiopulmonary bypass were treated with recombinant activated fac...

During the early events of coagulation of human blood by the intrinsic pathway, factor XII is activated to a form which can activate factor XI, and is proteolytically fragmented to smaller species (30,000 daltons and 70,000 daltons) which have lost most of the ability to activate factor XI but which can activate prekallikrein rapidly. The effect of these fragments on factor VII was studied. It ...

Resistance to thyroid hormone is an uncommon condition. We report the clinical and laboratory findings of a case with both resistance to thyroid hormone and, a reduced capacity to produce and respond to thyroid hormone. RTH is a disorder characterized by elevated circulating thyroid hormones, state of non-suppressed pituitary TSH secretion and refractoriness to hormone action in peripheral tiss...

In This Issue: • NovoSeven • Therapeutic Interchanges Introduction: Recombinant human activated Factor VII (rFVIIa), or NovoSeven, is a hemostatic agent which is structurally similar to human plasma-derived coagulation Factor VIIa. Recombinant FVIIa is currently licensed by the US Food and Drug Administration (FDA) in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX o...

abstract  introduction: during extrinsic coagulation pathway, a complex is developed between factor vii, calcium and tissue factor (a cell membrane lipoprotein that is exposed after cell injury). factor vii needs calcium and vitamin k for its biologic activation. coronary artery disease (cad) can be induced by increased level and activity of the coagulation factors vii, viii and ix. in postmeno...

Blood coagulation Factor M was purified 100,000fold from fresh frozen human plasma to apparent homogeneity with a yield of 30% based on coagulation assay. The molecular weight estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was 48,000. Factor VI1 is composed of a single polypeptide chain with the NHz-terminal sequence Ala-Asn-AlaPhe-Leu-(G1a)-(Gla)-Leu-(Arg)-Pro. It is co...